A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.

• Status: Completed
• Trial end date: 1995-12-01

Summary

The purpose of this study is to compare the safety and effectiveness of abciximab, an anti-platelet therapy, versus placebo in patients undergoing percutaneous coronary intervention when administered in combination with two different heparin regimens. Please see attached results.

• Phase: Phase 3

Details

• Lead Sponsor: Centocor, Inc.
• Treatments: Abciximab; Antibodies, Monoclonal; Calcium heparin; Heparin; Immunoglobulin Fab Fragments